Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Short Communication
Authors: Deck, Benjamin L.a; * | Rick, Jacquelinea | Xie, Sharon X.b | Chen-Plotkin, Alicea | Duda, John E.a; e | Morley, James F.a; e | Chahine, Lana M.a | Dahodwala, Nabilaa | Trojanowski, John Q.c | Weintraub, Daniela; d; e
Affiliations: [a] Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [b] Department of Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [c] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [d] Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [e] Parkinson’s Disease Research, Education and Clinical Center (PADRECC), Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
Correspondence: [*] Correspondence to: Benjamin L. Deck, BS, 330 South 9th Street, Philadelphia, PA 19107, USA. Tel.: +1 215 829 7104; Fax: +1 215 829 6606; E-mail: benjamin.deck@uphs.upenn.edu.
Abstract: Background:The relationship between statins and cognition in Parkinson’s disease (PD) is poorly understood. Objectives:Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. Methods:Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PD participants longitudinally. Results:At baseline, statin users (SU; N = 129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N = 184). In Cross-sectional analysis, SU performed better on global cognition, Trails B, semantic fluency, and phonemic fluency tasks. Rate of long-term global cognitive (Dementia Rating Scale-2 and MoCA) decline was significantly less in SU.
Keywords: Apolipoprotein A-I, cognition, hydroxymethylglutaryl-CoA reductase inhibitors, longitudinal studies, Parkinson’s disease, reactive oxygen species
DOI: 10.3233/JPD-171113
Journal: Journal of Parkinson's Disease, vol. 7, no. 4, pp. 661-667, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl